Glazer Capital LLC’s Coherus Oncology CHRS Stock Holding History

Glazer Capital LLC’s Portfolio CHRS Stock Details CHRS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-1	Closed	–	–	245
2025 Q1	$0	Buy	+1	New	+$1	﹤0.01%	191

Other funds holding CHRS

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CWG

C WorldWide Group Copenhagen, Denmark $4.66B AUM 11.67% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Glazer Capital LLC's CHRS Position: Q2 2025 in Review

Glazer Capital LLC sold out of Coherus Oncology (CHRS) in Q2 2025, closing a stake of 1 share.

Glazer Capital LLC first reported a position in CHRS in Q1 2025 and held it in 1 quarter. The position peaked at $0 in Q1 2025. 112 funds tracked by Wall St. Rank hold CHRS as of Q2 2025.

Glazer Capital LLC reported no remaining Coherus Oncology position as of Q2 2025 after selling out during the quarter.
Glazer Capital LLC sold 1 Coherus Oncology share in Q2 2025.
Glazer Capital LLC first reported a position in Coherus Oncology in Q1 2025 and held it in 1 quarter.
Glazer Capital LLC's Coherus Oncology position peaked at $0 in Q1 2025.
112 funds tracked by Wall St. Rank held Coherus Oncology as of Q2 2025.

Based on Glazer Capital LLC's 13F filing for Q2 2025, filed 14 Aug 2025.